Hong L Tiv
Overview
Explore the profile of Hong L Tiv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
1709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kohler J, Zhao Y, Li J, Gokhale P, Tiv H, Knott A, et al.
Mol Cancer Ther
. 2021 Feb;
20(4):641-654.
PMID: 33536188
gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB pathways. Within the MAPK pathway, ERK1/2...
2.
Howard T, Oberlick E, Rees M, Arnoff T, Pham M, Brenan L, et al.
Clin Cancer Res
. 2020 Jul;
26(18):4995-5006.
PMID: 32631955
Purpose: Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit and efficacy against preclinical models of rhabdoid tumor. Experimental Design:...
3.
Weisberg E, Meng C, Case A, Sattler M, Tiv H, Gokhale P, et al.
Leukemia
. 2020 Mar;
34(9):2543.
PMID: 32144400
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Weisberg E, Meng C, Case A, Tiv H, Gokhale P, Buhrlage S, et al.
J Cell Mol Med
. 2020 Jan;
24(5):2968-2980.
PMID: 31967735
Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA-approved FLT3 inhibitor for newly diagnosed patients with FLT3...
5.
Weisberg E, Meng C, Case A, Tiv H, Gokhale P, Toure A, et al.
J Cell Mol Med
. 2020 Jan;
24(3):2145-2156.
PMID: 31943762
Mutations in the E3 ubiquitin ligase CBL, found in several myeloid neoplasms, lead to decreased ubiquitin ligase activity. In murine systems, these mutations are associated with cytokine-independent proliferation, thought to...
6.
Weisberg E, Meng C, Case A, Sattler M, Tiv H, Gokhale P, et al.
Leukemia
. 2019 Aug;
34(2):625-629.
PMID: 31455850
No abstract available.
7.
Weisberg E, Meng C, Case A, Sattler M, Tiv H, Gokhale P, et al.
Br J Haematol
. 2019 Jul;
187(4):488-501.
PMID: 31309543
Mutations in two type-3 receptor tyrosine kinases (RTKs), KIT and FLT3, are common in both acute myeloid leukaemia (AML) and systemic mastocytosis (SM) and lead to hyperactivation of key signalling...
8.
Bandopadhayay P, Piccioni F, ORourke R, Ho P, Gonzalez E, Buchan G, et al.
Nat Commun
. 2019 Jun;
10(1):2400.
PMID: 31160565
BET-bromodomain inhibition (BETi) has shown pre-clinical promise for MYC-amplified medulloblastoma. However, the mechanisms for its action, and ultimately for resistance, have not been fully defined. Here, using a combination of...
9.
Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E, et al.
Nature
. 2019 May;
569(7757):503-508.
PMID: 31068700
Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to study genetic variants, candidate targets, and small-molecule...
10.
Howard T, Arnoff T, Song M, Giacomelli A, Wang X, Hong A, et al.
Cancer Res
. 2019 Feb;
79(9):2404-2414.
PMID: 30755442
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric cancers that respond poorly to current therapies. In this study, we screened several MRT cell lines with large-scale RNAi, CRISPR-Cas9, and small-molecule...